Document:

Form of Medium-Term Notes, Series K

 Exhibit 4.1 

[Face of Note] 

Unless this certificate is presented by an authorized representative of The Depository Trust Company, a New York corporation
(“DTC”), to the Company or its agent for registration of transfer, exchange or payment, and any certificate issued is registered in the name of Cede & Co. or in such other name as requested by an authorized representative
of DTC (and any payment is made to Cede & Co. or such other entity as is requested by an authorized representative of DTC), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL inasmuch as the
registered owner hereof, Cede & Co., has an interest herein. 
  

	 CUSIP NO. 94986R6T3 
	
FACE AMOUNT: $                   
          

 REGISTERED NO.      

WELLS FARGO & COMPANY 

MEDIUM-TERM NOTE, SERIES K 

Due Nine Months or More From Date of Issue 

Principal at Risk Securities Linked to a Global ETF Basket 

due June 26, 2020 

WELLS FARGO & COMPANY, a corporation duly organized and existing under the laws of the State of Delaware (hereinafter
called the “Company,” which term includes any successor corporation under the Indenture hereinafter referred to), for value received, hereby promises to pay to CEDE & Co., or registered assigns, an amount equal to the
Redemption Amount (as defined below), in such coin or currency of the United States of America as at the time of payment is legal tender for payment of public and private debts, on the Stated Maturity Date. The “Initial Stated Maturity
Date” shall be June 26, 2020. If the Calculation Day (as defined below) is not postponed for any Basket Component (as defined below), the Initial Stated Maturity Date will be the “Stated Maturity Date.” If the
Calculation Day is postponed for any Basket Component, the “Stated Maturity Date” shall be the later of (i) the Initial Stated Maturity Date and (ii) the third Business Day (as defined below) after the last Calculation Day
as postponed. This Security shall not bear any interest. 
 Any payments on this Security at Maturity will be made against
presentation of this Security at the office or agency of the Company maintained for that purpose in the City of Minneapolis, Minnesota and at any other office or agency maintained by the Company for such purpose. 

“Face Amount” shall mean, when used with respect to this Security, the amount set forth on the face of this
Security as its “Face Amount.” 

 Determination of Redemption Amount 

The “Redemption Amount” of this Security will equal: 

 

	 	•	 	 if the Ending Price is greater than the Starting Price: the Face Amount plus: 

 
 

 
  

	 	•	 	 if the Ending Price is less than or equal to the Starting Price, but greater than or equal to the Threshold
Price: the Face Amount; or 

  

	 	•	 	 if the Ending Price is less than the Threshold Price: the Face Amount minus: 

 
 

 
 All calculations with respect to the Redemption Amount will be rounded to the nearest one
hundred-thousandth, with five one-millionths rounded upward (e.g., 0.000005 would be rounded to 0.00001); and the Redemption Amount will be rounded to the nearest cent, with one-half cent rounded upward. 

“Basket” shall mean a basket comprised of the following Basket Components, with the return of each Basket
Component having the weighting noted parenthetically: SPDR S&P 500 ETF Trust (50%); iShares Russell 2000 ETF (25%); and iShares MSCI EAFE ETF (25%). 

“Basket Component” shall mean each of the SPDR S&P 500 ETF Trust, iShares Russell 2000 ETF and iShares
MSCI EAFE ETF. 
 “Underlying Index” shall mean each of the S&P 500 Index, Russell 2000 Index and MSCI
EAFE Index. 
 The “Pricing Date” shall mean June 23, 2017. 

The “Starting Price” is 100. 

The “Ending Price” will be calculated based on the weighted returns of the Basket Components and will be
equal to the product of (i) 100 and (ii) an amount equal to 1 plus the sum of: (A) 50% of the Component Return of the SPDR S&P 500 ETF Trust; (B) 25% of the Component Return of the iShares Russell 2000 ETF; and (C) 25%
of the Component Return of the iShares MSCI EAFE ETF. 

  
 2 

 The “Component Return” of a Basket Component will be equal to:

 Final Component Price – Initial Component Price 

Initial Component Price 

where, 
  

	 	•	 	 the “Initial Component Price” is the Fund Closing Price of such Basket Component on the Pricing
Date; and 

  

	 	•	 	 the “Final Component Price” will be the Fund Closing Price of such Basket Component on the
Calculation Day. 

 The Initial Component Prices of the Basket Components are as follows: SPDR S&P 500
ETF Trust ($243.13); iShares Russell 2000 ETF ($140.91); and iShares MSCI EAFE ETF ($65.14). 
 The “Fund Closing
Price” with respect to a Basket Component on any Trading Day means the product of (i) the Closing Price of one share of such Basket Component (or one unit of any other security for which a Fund Closing Price must be determined) on such
Trading Day and (ii) the Adjustment Factor applicable to such Basket Component on such Trading Day. 
 The
“Closing Price” with respect to a share of a Basket Component (or one unit of any other security for which a Closing Price must be determined) on any Trading Day means the price, at the scheduled weekday closing time, without regard
to after hours or any other trading outside the regular trading session hours, of the share on the principal United States securities exchange registered under the Securities Exchange Act of 1934, as amended, on which the share (or any such other
security) is listed or admitted to trading. 
 The “Adjustment Factor” means, with respect to a share of a
Basket Component (or one unit of any other security for which a Fund Closing Price must be determined), 1.0, subject to adjustment in the event of certain events affecting the shares of such Basket Component. See “Anti-dilution Adjustments
Relating To A Basket Component; Alternate Calculation—Anti-dilution Adjustments” below. 
 The “Threshold
Price” is 90, which is equal to 90% of the Starting Price. 
 The “Participation Rate” is 116%.

 “Business Day” shall mean a day, other than a Saturday or Sunday, that is neither a legal holiday nor a
day on which banking institutions are authorized or required by law or regulation to close in New York, New York. 
 A
“Trading Day” with respect to a Basket Component means a day, as determined by the Calculation Agent, on which the Relevant Stock Exchange (as defined below) and each Related Futures or Options Exchange (as defined below) with
respect to such Basket Component, or any 

  
 3 

 
successor thereto, if applicable, are scheduled to be open for trading for their respective regular trading sessions. 

The “Related Futures or Options Exchange” for a Basket Component means each exchange or quotation system
where trading has a material effect (as determined by the Calculation Agent) on the overall market for futures or options contracts relating to such Basket Component. 

The “Relevant Stock Exchange” for a Basket Component means the primary exchange or quotation system on which
shares (or other applicable securities) of such Basket Component are traded, as determined by the Calculation Agent. 
 The
“Calculation Day” shall be June 23, 2020. If such day is not a Trading Day with respect to any Basket Component, the Calculation Day for each Basket Component will be postponed to the next succeeding Trading Day that is a
Trading Day with respect to each Basket Component. The Calculation Day is also subject to postponement due to the occurrence of a Market Disruption Event (as defined below). If a Market Disruption Event occurs or is continuing with respect to a
Basket Component on the Calculation Day, such Calculation Day for such Basket Component will be postponed to the first succeeding Trading Day for such Basket Component on which a Market Disruption Event for such Basket Component has not occurred and
is not continuing; however, if such first succeeding Trading Day has not occurred as of the eighth Trading Day for such Basket Component after the originally scheduled Calculation Day, that eighth Trading Day shall be deemed to be the Calculation
Day. If the Calculation Day has been postponed eight Trading Days for a Basket Component after the originally scheduled Calculation Day for such Basket Component, and a Market Disruption Event occurs or is continuing with respect to such Basket
Component on such eighth Trading Day, the Calculation Agent will determine the Closing Price of such Basket Component on such eighth Trading Day based on its good faith estimate of the value of the shares (or other applicable securities) of such
Basket Component as of the Close of Trading (as defined below) on such eighth Trading Day. Notwithstanding the postponement of the Calculation Day for a particular Basket Component due to a Market Disruption Event with respect to such Basket
Component, the originally scheduled Calculation Day will remain the Calculation Day for any Basket Component not affected by a Market Disruption Event. See “—Market Disruption Events.” 

“Calculation Agent Agreement” shall mean the Calculation Agent Agreement dated as of March 18, 2015
between the Company and the Calculation Agent, as amended from time to time. 
 “Calculation Agent” shall
mean the Person that has entered into the Calculation Agent Agreement with the Company providing for, among other things, the determination of the Ending Price and the Redemption Amount, which term shall, unless the context otherwise requires,
include its successors under such Calculation Agent Agreement. The initial Calculation Agent shall be Wells Fargo Securities, LLC. Pursuant to the Calculation Agent Agreement, the Company may appoint a different Calculation Agent from time to time
after the initial issuance of this Security without the consent of the Holder of this Security and without notifying the Holder of this Security. 

  
 4 

 Market Disruption Events 

A “Market Disruption Event” means, with respect to a Basket Component, any of the following events as
determined by the Calculation Agent in its sole discretion: 
  

	 	(A)	 The occurrence or existence of a material suspension of or limitation imposed on trading by the Relevant Stock
Exchange or otherwise relating to the shares (or other applicable securities) of such Basket Component or any Successor Fund (as defined below) on the Relevant Stock Exchange at any time during the one-hour period that ends at the Close of Trading
on such day, whether by reason of movements in price exceeding limits permitted by such Relevant Stock Exchange or otherwise. 

  

	 	(B)	 The occurrence or existence of a material suspension of or limitation imposed on trading by any Related
Futures or Options Exchange or otherwise in futures or options contracts relating to the shares (or other applicable securities) of such Basket Component or any Successor Fund on any Related Futures or Options Exchange at any time during the
one-hour period that ends at the Close of Trading on that day, whether by reason of movements in price exceeding limits permitted by the Related Futures or Options Exchange or otherwise. 

 

	 	(C)	 The occurrence or existence of any event, other than an early closure, that materially disrupts or impairs the
ability of market participants in general to effect transactions in, or obtain market values for, shares (or other applicable securities) of such Basket Component or any Successor Fund on the Relevant Stock Exchange at any time during the one-hour
period that ends at the Close of Trading on that day. 

  

	 	(D)	 The occurrence or existence of any event, other than an early closure, that materially disrupts or impairs the
ability of market participants in general to effect transactions in, or obtain market values for, futures or options contracts relating to shares (or other applicable securities) of such Basket Component or any Successor Fund on any Related Futures
or Options Exchange at any time during the one-hour period that ends at the Close of Trading on that day. 

  

	 	(E)	 The closure of the Relevant Stock Exchange or any Related Futures or Options Exchange with respect to such
Basket Component or any Successor Fund prior to its Scheduled Closing Time unless the earlier closing time is announced by the Relevant Stock Exchange or Related Futures or Options Exchange, as applicable, at least one hour prior to the earlier of
(1) the actual closing time for the regular trading session on such Relevant Stock Exchange or Related Futures or Options Exchange, as applicable, and (2) the submission deadline for orders to be entered into the Relevant Stock Exchange or
Related Futures or Options Exchange, as applicable, system for execution at the Close of Trading on that day. 

  
 5 

	 	(F)	 The Relevant Stock Exchange or any Related Futures or Options Exchange with respect to such Basket Component
or any Successor Fund fails to open for trading during its regular trading session. 

 For purposes of
determining whether a Market Disruption Event has occurred: 
  

	 	(1)	 “Close of Trading” means the Scheduled Closing Time of the Relevant Stock Exchange with
respect to such Basket Component or any Successor Fund; and 

  

	 	(2)	 the “Scheduled Closing Time” of the Relevant Stock Exchange or any Related Futures or Options
Exchange on any Trading Day for such Basket Component or any Successor Fund means the scheduled weekday closing time of such Relevant Stock Exchange or Related Futures or Options Exchange on such Trading Day, without regard to after hours or any
other trading outside the regular trading session hours. 

 Anti-dilution Adjustments Relating To A Basket Component; Alternate
Calculation 
 Anti-dilution Adjustments 

The Calculation Agent will adjust the Adjustment Factor with respect to a Basket Component as specified below if any of the
events specified below occurs with respect to such Basket Component and the effective date or ex-dividend date, as applicable, for such event is after the Pricing Date and on or prior to the Calculation Day. 

The adjustments specified below do not cover all events that could affect a Basket Component. The Calculation Agent may, in
its sole discretion, make additional adjustments to any terms of this Security upon the occurrence of other events that affect or could potentially affect the market price of, or shareholder rights in, such Basket Component, with a view to
offsetting, to the extent practical, any such change, and preserving the relative investment risks of this Security. In addition, the Calculation Agent may, in its sole discretion, make adjustments or a series of adjustments that differ from those
described herein if the Calculation Agent determines that such adjustments do not properly reflect the economic consequences of the events specified herein or would not preserve the relative investment risks of this Security. All determinations made
by the Calculation Agent in making any adjustments to the terms of this Security, including adjustments that are in addition to, or that differ from, those described herein, will be made in good faith and a commercially reasonable manner, with the
aim of ensuring an equitable result. In determining whether to make any adjustment to the terms of this Security, the Calculation Agent may consider any adjustment made by the Options Clearing Corporation or any other equity derivatives clearing
organization on options contracts on the affected Basket Component. 
 For any event described below, the Calculation Agent
will not be required to adjust the Adjustment Factor unless the adjustment would result in a change to the Adjustment Factor then in effect of at least 0.10%. The Adjustment Factor resulting from any adjustment will be rounded up or down, as
appropriate, to the nearest one-hundred thousandth. 

  
 6 

	 	(A)	 Stock Splits and Reverse Stock Splits 

If a stock split or reverse stock split has occurred, then once such split has become effective, the Adjustment Factor will
be adjusted to equal the product of the prior Adjustment Factor and the number of securities which a holder of one share (or other applicable security) of the Basket Component before the effective date of such stock split or reverse stock split
would have owned or been entitled to receive immediately following the applicable effective date. 
  

	 	(B)	 Stock Dividends 

If a dividend or distribution of shares (or other applicable securities) to which this Security is linked has been made by a
Basket Component ratably to all holders of record of such shares (or other applicable security), then the Adjustment Factor will be adjusted on the ex-dividend date to equal the prior Adjustment Factor plus the product of the prior Adjustment Factor
and the number of shares (or other applicable security) of such Basket Component which a holder of one share (or other applicable security) of such Basket Component before the ex-dividend date would have owned or been entitled to receive immediately
following that date; provided, however, that no adjustment will be made for a distribution for which the number of securities of such Basket Component paid or distributed is based on a fixed cash equivalent value. 

 

	 	(C)	 Extraordinary Dividends 

If an Extraordinary Dividend (as defined below) has occurred, then the Adjustment Factor will be adjusted on the ex-dividend
date to equal the product of the prior Adjustment Factor and a fraction, the numerator of which is the Closing Price per share (or other applicable security) of such Basket Component on the Trading Day preceding the ex-dividend date, and the
denominator of which is the amount by which the Closing Price per share (or other applicable security) of such Basket Component on the Trading Day preceding the ex-dividend date exceeds the Extraordinary Dividend Amount (as defined below). 

For purposes of determining whether an Extraordinary Dividend has occurred: 

 

	 	(1)	 “Extraordinary Dividend” means any cash dividend or distribution (or portion thereof) that
the Calculation Agent determines, in its sole discretion, is extraordinary or special; and 

  

	 	(2)	 “Extraordinary Dividend Amount” with respect to an Extraordinary Dividend for the securities
of such Basket Component will equal the amount per share (or other applicable security) of such Basket Component of the applicable cash dividend or distribution that is attributable to the Extraordinary Dividend, as determined by the Calculation
Agent in its sole discretion. 

  
 7 

 A distribution on the securities of such Basket Component described below under
the section entitled “—Reorganization Events” below that also constitutes an Extraordinary Dividend will only cause an adjustment pursuant to that “—Reorganization Events” section. 

 

	 	(D)	 Other Distributions 

If a Basket Component declares or makes a distribution to all holders of the shares (or other applicable security) of such
Basket Component of any non-cash assets, excluding dividends or distributions described under the section entitled “—Stock Dividends” above, then the Calculation Agent may, in its sole discretion, make such adjustment (if any) to the
Adjustment Factor as it deems appropriate in the circumstances. If the Calculation Agent determines to make an adjustment pursuant to this paragraph, it will do so with a view to offsetting, to the extent practical, any change in the economic
position of a holder of this Security that results solely from the applicable event. 
  

	 	(E)	 Reorganization Events 

If a Basket Component, or any Successor Fund, is subject to a merger, combination, consolidation or statutory exchange of
securities with another exchange traded fund, and such Basket Component to which this Security is linked is not the surviving entity (a “Reorganization Event”), then, on or after the date of such event, the Calculation Agent shall,
in its sole discretion, make an adjustment to the Adjustment Factor or the method of determining the Redemption Amount or any other terms of this Security as the Calculation Agent determines appropriate to account for the economic effect on this
Security of such event, and determine the effective date of that adjustment. If the Calculation Agent determines that no adjustment that it could make will produce a commercially reasonable result, then the Calculation Agent may deem such event a
Liquidation Event (as defined below). 
 Liquidation Events 

If a Basket Component is de-listed, liquidated or otherwise terminated (a “Liquidation Event”), and a
successor or substitute exchange traded fund exists that the Calculation Agent determines, in its sole discretion, to be comparable to such Basket Component, then, upon the Calculation Agent’s notification of that determination to the Trustee
and the Company, any subsequent Fund Closing Price for such Basket Component will be determined by reference to the Fund Closing Price of such successor or substitute exchange traded fund (such exchange traded fund being referred to herein as a
“Successor Fund”), with such adjustments as the Calculation Agent determines are appropriate to account for the economic effect of such substitution on the holder of this Security. 

If a Basket Component undergoes a Liquidation Event prior to, and such Liquidation Event is continuing on, the date that any
Fund Closing Price of such Basket Component is to be determined and the Calculation Agent determines that no Successor Fund is available at such 

  
 8 

 
time, then the Calculation Agent will, in its discretion, calculate the Fund Closing Price for such Basket Component on such date by a computation methodology that the Calculation Agent
determines will as closely as reasonably possible replicate such Basket Component, provided that if the Calculation Agent determines in its discretion that it is not practicable to replicate such Basket Component (including but not limited to the
instance in which the sponsor of the index underlying such Basket Component discontinues publication of that index), then the Calculation Agent will calculate the Fund Closing Price for such Basket Component in accordance with the formula last used
to calculate such Fund Closing Price before such Liquidation Event, but using only those securities that were held by such Basket Component immediately prior to such Liquidation Event without any rebalancing or substitution of such securities
following such Liquidation Event. 
 Notwithstanding the foregoing, if the PowerShares DB Commodity Index Tracking Fund
undergoes a Liquidation Event prior to, and such Liquidation Event is continuing on the Calculation Day, and the Calculation Agent determines in its discretion that (i) no Successor Fund is available at such time and (ii) it is not
practicable to replicate the PowerShares DB Commodity Index Tracking Fund, then the Calculation Agent will calculate the Fund Closing Price of the PowerShares DB Commodity Index Tracking Fund in good faith and in a commercially reasonable manner.

 If a Successor Fund is selected or the Calculation Agent calculates the Fund Closing Price as a substitute for such
Basket Component, such Successor Fund or Fund Closing Price will be used as a substitute for such Basket Component for all purposes, including for purposes of determining whether a Market Disruption Event exists. 

If any event is both a Reorganization Event and a Liquidation Event, such event will be treated as a Reorganization Event for
purposes of this Security unless the Calculation Agent makes the determination referenced in the last sentence of the section entitled “—Anti-dilution Adjustments—Reorganization Events” above. 

Alternate Calculation 

If at any time the method of calculating a Basket Component or a Successor Fund, or the related Underlying Index, is changed
in a material respect, or if a Basket Component or a Successor Fund is in any other way modified so that such Basket Component does not, in the opinion of the Calculation Agent, fairly represent the price of the securities of such Basket Component
or such Successor Fund had such changes or modifications not been made, then the Calculation Agent may, at the close of business in New York City on the date that any Fund Closing Price is to be determined, make such calculations and adjustments as,
in the good faith judgment of the Calculation Agent, may be necessary in order to arrive at a Closing Price of an exchange traded fund comparable to such Basket Component or such Successor Fund, as the case may be, as if such changes or
modifications had not been made, and calculate the Fund Closing Price and the Redemption Amount with reference to such adjusted Closing Price of such Basket Component or such Successor Fund, as applicable. 

  
 9 

 Calculation Agent 

The Calculation Agent will determine the Redemption Amount and the Ending Price. In addition, the Calculation Agent will
(i) determine if adjustments are required to the Fund Closing Price and/or the Adjustment Factor of a Basket Component under the circumstances described in this Security, (ii) if a Basket Component undergoes a Liquidation Event, select a
Successor Fund or, if no Successor Fund is available, determine the Fund Closing Price of such Basket Component, and (iii) determine whether a Market Disruption Event or non-Trading Day has occurred. 

The Company covenants that, so long as this Security is Outstanding, there shall at all times be a Calculation Agent (which
shall be a broker-dealer, bank or other financial institution) with respect to this Security. 

All determinations made by the Calculation Agent with respect to this Security will be at the sole discretion of the
Calculation Agent and, in the absence of manifest error, will be conclusive for all purposes and binding on the Company and the Holder of this Security. 

Tax Considerations 

The Company agrees, and by acceptance of a beneficial ownership interest in this Security each Holder of this Security will be
deemed to have agreed (in the absence of a statutory, regulatory, administrative or judicial ruling to the contrary), for United States federal income tax purposes to treat this Security as a prepaid derivative contract that is an “open
transaction.” 
 Redemption and Repayment 

This Security is not subject to redemption at the option of the Company or repayment at the option of the Holder hereof prior
to June 26, 2020. This Security is not entitled to any sinking fund. 
 Acceleration 

If an Event of Default, as defined in the Indenture, with respect to this Security shall occur and be continuing, the
Redemption Amount (calculated as set forth in the next sentence) of this Security may be declared due and payable in the manner and with the effect provided in the Indenture. The amount payable to the Holder hereof upon any acceleration permitted
under the Indenture will be equal to the Redemption Amount hereof calculated as provided herein as though the date of acceleration was the Calculation Day. 
  

 

Reference is hereby made to the further provisions of this Security set forth on the reverse hereof, which further provisions
shall for all purposes have the same effect as if set forth at this place. 
 Unless the certificate of authentication
hereon has been executed by the Trustee referred to on the reverse hereof by manual signature or its duly authorized agent under the Indenture referred to on the reverse hereof by manual signature, this Security shall not be entitled to any benefit
under the Indenture or be valid or obligatory for any purpose. 

  
 10 

 IN WITNESS WHEREOF, the Company has caused this instrument to be duly executed
under its corporate seal. 
 DATED:
                                 

 

			
	WELLS FARGO & COMPANY

 
			
		
	By:	 	 
		
	Its:	 	 

 [SEAL] 
  

					
	Attest:	 	 
			
		 	Its:	 	 

  

			
	 TRUSTEE’S CERTIFICATE OF

AUTHENTICATION
 This is one of the Securities of the

series designated therein described
 in the within-mentioned Indenture.

	
	 CITIBANK, N.A.,

      as Trustee

		
	By:	 	 
		 	Authorized Signature
	
	OR                    
	
	 WELLS FARGO BANK, N.A.,

  as Authenticating Agent for the Trustee

		
	By:	 	 
		 	Authorized Signature

  
 11 

 [Reverse of Note] 

WELLS FARGO & COMPANY 

MEDIUM-TERM NOTE, SERIES K 

Due Nine Months or More From Date of Issue 

Principal at Risk Securities Linked to a Global ETF Basket 

due June 26, 2020 

This Security is one of a duly authorized issue of securities of the Company (herein called the
“Securities”), issued and to be issued in one or more series under an indenture dated as of July 21, 1999, as amended or supplemented from time to time (herein called the “Indenture”), between the Company and
Citibank, N.A., as Trustee (herein called the “Trustee,” which term includes any successor trustee under the Indenture), to which Indenture and all indentures supplemental thereto reference is hereby made for a statement of the
respective rights, limitations of rights, duties and immunities thereunder of the Company, the Trustee and the Holders of the Securities, and of the terms upon which the Securities are, and are to be, authenticated and delivered. This Security is
one of the series of the Securities designated as Medium-Term Notes, Series K, of the Company, which series is limited to an aggregate principal amount or face amount, as applicable, of $25,000,000,000 or the equivalent thereof in one or more
foreign or composite currencies. The amount payable on the Securities of this series may be determined by reference to the performance of one or more equity-, commodity- or currency-based indices, exchange traded funds, securities, commodities,
currencies, statistical measures of economic or financial performance, or a basket comprised of two or more of the foregoing, or any other market measure or may bear interest at a fixed rate or a floating rate. The Securities of this series may
mature at different times, be redeemable at different times or not at all, be repayable at the option of the Holder at different times or not at all and be denominated in different currencies. 

Article Sixteen of the Indenture shall not apply to this Security. 

The Securities are issuable only in registered form without coupons and will be either
(a) book-entry securities represented by one or more Global Securities recorded in the book-entry system maintained by the Depositary or (b) certificated
securities issued to and registered in the names of, the beneficial owners or their nominees. 
 The Company agrees, to the
extent permitted by law, not to voluntarily claim the benefits of any laws concerning usurious rates of interest against a Holder of this Security. 

Modification and Waivers 

The Indenture permits, with certain exceptions as therein provided, the amendment thereof and the modification of the rights
and obligations of the Company and the rights of the Holders of the Securities of each series to be affected under the Indenture at any time by the Company and the Trustee with the consent of the Holders of a majority in principal amount of the
Securities at the 

  
 12 

 
time Outstanding of all series to be affected, acting together as a class. The Indenture also contains provisions permitting the Holders of a majority in principal amount of the Securities of all
series at the time Outstanding affected by certain provisions of the Indenture, acting together as a class, on behalf of the Holders of all Securities of such series, to waive compliance by the Company with those provisions of the Indenture. Certain
past defaults under the Indenture and their consequences may be waived under the Indenture by the Holders of a majority in principal amount of the Securities of each series at the time Outstanding, on behalf of the Holders of all Securities of such
series. Solely for the purpose of determining whether any consent, waiver, notice or other action or Act to be taken or given by the Holders of Securities pursuant to the Indenture has been given or taken by the Holders of Outstanding Securities in
the requisite aggregate principal amount, the principal amount of this Security will be deemed to be equal to the amount set forth on the face hereof as the “Face Amount” hereof. Any such consent or waiver by the Holder of this Security
shall be conclusive and binding upon such Holder and upon all future Holders of this Security and of any Security issued upon the registration of transfer hereof or in exchange herefor or in lieu hereof, whether or not notation of such consent or
waiver is made upon this Security. 
 Defeasance 

Section 403 and Article Fifteen of the Indenture and the provisions of clause (ii) of Section 401(1)(B) of the
Indenture, relating to defeasance at any time of (a) the entire indebtedness on this Security and (b) certain restrictive covenants and certain Events of Default, upon compliance by the Company with certain conditions set forth therein,
shall not apply to this Security. The remaining provisions of Section 401 of the Indenture shall apply to this Security. 
 Authorized
Denominations 
 This Security is issuable only in registered form without coupons in denominations of $1,000 or any
amount in excess thereof which is an integral multiple of $1,000. 
 Registration of Transfer 

Upon due presentment for registration of transfer of this Security at the office or agency of the Company in the City of
Minneapolis, Minnesota, a new Security or Securities of this series, with the same terms as this Security, in authorized denominations for an equal aggregate Face Amount will be issued to the transferee in exchange herefor, as provided in the
Indenture and subject to the limitations provided therein and to the limitations described below, without charge except for any tax or other governmental charge imposed in connection therewith. 

This Security is exchangeable for definitive Securities in registered form only if (x) the Depositary notifies the
Company that it is unwilling or unable to continue as Depositary for this Security or if at any time the Depositary ceases to be a clearing agency registered under the Securities Exchange Act of 1934, as amended, and a successor depositary is not
appointed within 90 days after the Company receives such notice or becomes aware of such ineligibility, (y) the Company in its sole discretion determines that this Security shall be exchangeable for definitive Securities in registered form
and notifies the Trustee thereof or (z) an Event of Default with respect to the Securities represented hereby has occurred and is continuing. If this Security is exchangeable pursuant to the preceding sentence, it shall be exchangeable for
definitive Securities in registered 

  
 13 

 
form, having the same date of issuance, Stated Maturity Date and other terms and of authorized denominations aggregating a like amount. 

This Security may not be transferred except as a whole by the Depositary to a nominee of the Depositary or by a nominee of the
Depositary to the Depositary or another nominee of the Depositary or by the Depositary or any such nominee to a successor of the Depositary or a nominee of such successor. Except as provided above, owners of beneficial interests in this Global
Security will not be entitled to receive physical delivery of Securities in definitive form and will not be considered the Holders hereof for any purpose under the Indenture. 

Prior to due presentment of this Security for registration of transfer, the Company, the Trustee and any agent of the Company
or the Trustee may treat the Person in whose name this Security is registered as the owner hereof for all purposes, whether or not this Security be overdue, and neither the Company, the Trustee nor any such agent shall be affected by notice to the
contrary. 
 Obligation of the Company Absolute 

No reference herein to the Indenture and no provision of this Security or the Indenture shall alter or impair the obligation
of the Company, which is absolute and unconditional, to pay the Redemption Amount at the times, place and rate, and in the coin or currency, herein prescribed, except as otherwise provided in this Security. 

No Personal Recourse 

No recourse shall be had for the payment of the Redemption Amount, or for any claim based hereon, or otherwise in respect
hereof, or based on or in respect of the Indenture or any indenture supplemental thereto, against any incorporator, stockholder, officer or director, as such, past, present or future, of the Company or any successor corporation, whether by virtue of
any constitution, statute or rule of law, or by the enforcement of any assessment or penalty or otherwise, all such liability being, by the acceptance hereof and as part of the consideration for the issuance hereof, expressly waived and released.

 Defined Terms 

All terms used in this Security which are defined in the Indenture shall have the meanings assigned to them in the Indenture
unless otherwise defined in this Security. 
 Governing Law 

This Security shall be governed by and construed in accordance with the law of the State of New York, without regard to
principles of conflicts of laws. 

  
 14 

 ABBREVIATIONS 

The following abbreviations, when used in the inscription on the face of this instrument, shall be construed as though they
were written out in full according to applicable laws or regulations: 
  

					
	 TEN COM
	 	  -- 
	 	 as tenants in common

			
	 TEN ENT
	 	  -- 
	 	 as tenants by the entireties

			
	 JT TEN
	 	  -- 
	 	 as joint tenants with right

of survivorship and not
 as
tenants in common

  

									
	 UNIF GIFT MIN ACT
	 	  -- 
	 	 	 	 Custodian
	 	 
		 		 	(Cust)	 		 	(Minor)

  

	
	Under Uniform Gifts to Minors Act
	
	   

	(State)

 Additional abbreviations may also be used though not in the above list. 

FOR VALUE RECEIVED, the undersigned hereby sell(s) and transfer(s) unto 

 

	
	 Please Insert Social Security or
 Other
Identifying Number of Assignee

	
	   

  
  

 
  
  

 
 (PLEASE
PRINT OR TYPE NAME AND ADDRESS INCLUDING POSTAL ZIP CODE OF ASSIGNEE)

  
 15 

 the within Security of WELLS FARGO & COMPANY and does hereby irrevocably constitute and
appoint                                      attorney to
transfer the said Security on the books of the Company, with full power of substitution in the premises. 
 Dated:
                                         
        
  

	
	   

  

	
	   

 NOTICE: The signature to this assignment must correspond with the name as written upon the face of the
within instrument in every particular, without alteration or enlargement or any change whatever. 

  
 16MARINA
BIOTECH, INC.

17870
Castleton Street, Suite 250

City
of Industry, CA 91748

 

June
5, 2017

 

Erik
Emerson

19366
Green Lakes Lp

Bend,
OR 97702

 

Dear
Mr. Emerson:

 

We
are very pleased that you have decided to accept employment with Marina Biotech, Inc., a Delaware corporation (the “Company”),
effective upon the Effective Date (as defined below), and are writing to confirm the terms of your employment.

 

	Title/Duties:	You
    shall be employed as the Chief Commercial Officer of the Company and shall report to the Chief Executive Officer of the Company
    (the “CEO”). As Chief Operating Officer, you shall have the powers, responsibilities and authorities assigned
    to you by the CEO from time to time. You will devote such time and efforts as is reasonably necessary to the performance of
    your duties for the Company, which is anticipated to represent approximately 50% of your business time. Other than as expressly
    approved by the Company any services that you provide to others while employed by the Company shall not: (i) violate any restrictive
    covenants by which you are bound, including, but not limited to, your obligations as set forth in the Restrictive Covenant
    Agreement (as defined below) or (ii) otherwise interfere with your duties to the Company.
	 	 
	Start
    Date:	Your
    employment with the Company as Chief Commercial Officer (and your rights and obligations hereunder, other than as specifically
    set forth herein) will commence effective upon the closing of a single capital raising transaction by the Company involving
    the issuance by the Company of its equity (or equity-linked) securities yielding aggregate gross proceeds to the Company of
    not less than $5,000,000; provided, that the closing of such financing transaction occurs on or prior to December 31, 2017.

 

    	 	 	 

    	 

    

 

	Base
    Salary:	Base
    salary of $150,000 per year (“Base Salary”), payable in accordance with the Company’s payroll practices,
    for the period of time in which the allocation of your time remains at the 50% threshold.
	 	 
	Discretionary
    Bonus:	You
    will be entitled to receive a discretionary bonus as determined by the Board of Directors of the Company (the “Board”)
    in an amount up to 40% of your Base Salary, with the payment of such bonus to be based on the achievement of such corporate
    milestones / sales milestones / sales & marketing team milestones as shall be determined by the Board following good faith
    consultation with you.
	 	 
	Restricted
    Stock Grant:	The
    Company shall issue to you, in connection with your execution and delivery of this letter (and thus prior to and not contingent
    upon the Effective Date), 600,000 restricted shares of the common stock of the Company under the Company’s 2014 Long-Term
    Incentive Plan, with all of such shares to vest on the six (6) month anniversary of the date of this letter (provided that
    you and Symplmed have performed the obligations and satisfied the covenants applicable to you to the reasonable satisfaction
    of the Company pursuant to that certain Asset Purchase Agreement dated as of June 5, 2017 by and between the Company and Symplmed).
    The grant of such restricted shares of common stock shall be further evidenced by a separate grant agreement to be entered
    into between you and the Company. You hereby agree that you shall not sell more than 100,000 shares of the common stock granted
    to you pursuant to this letter during any calendar month.
	 	 
	Employee
    Benefits:	You
    shall be eligible to participate in all Company employee benefit plans and programs which the Company generally makes available
    to employees, subject to the terms of such plans and programs. However, nothing herein requires the Company to offer or maintain
    any benefit plan, program or practice, and the Company may modify, amend or terminate such plans, programs and practices at
    any time in its sole discretion.

 

    	 	2	 

    	 

    

 

	Paid
    Time Off:	You
    shall be entitled to fifteen (15) business days of paid vacation in each calendar year, subject to the policies and procedures
    of the Company concerning vacation and sick time.
	 	 
	Termination:	Your
    employment will be that of an at-will employee which means that either the Company or you can end the employment
    relationship at any time for any reason or for no reason, with or without notice, or with or without Cause (defined below).
    In the event that your employment with the Company terminates for any reason, you shall not be entitled to any severance amounts
    of any kind or other post termination payments, except as required by law (if any).
	 	 
	Return
    of Company Property:	You
    agree that, upon the termination of your employment with the Company for any reason, or upon any request by the Company at
    any time, you will immediately deliver to the Company (and will not keep in your possession, recreate or deliver to anyone
    else) any and all software, devices, records, data, notes, reports, proposals, lists, correspondence, specifications, drawings,
    blueprints, sketches, materials, equipment, other documents or property, or reproductions of any of the aforementioned items
    which you developed or which are connected in any way with your employment with the Company, or which otherwise belong to
    the Company, its successors or assigns.
	 	 
	Non-Solicitation/Confidentiality
    Agreement/Policies	As
    a condition of your employment, you hereby agree to execute and to be subject to the covenants and other provisions of the
    Company’s standard confidentiality, restrictive covenant and intellectual property agreement (the “Restrictive
    Covenant Agreement”), attached hereto as Schedule A and incorporated herein by reference. You also agree
    that you will comply with all Company policies and procedures.

 

    	 	3	 

    	 

    

 

This
letter and your employment will be governed by the law of the State of California. This letter may be executed in several counterparts,
each of which shall be deemed to be an original but all of which together will constitute one and the same instrument. The Company
may withhold from any payments any amounts required to be withheld by law. If any provision of this letter shall be declared to
be invalid or unenforceable, in whole or in part, such invalidity or unenforceability shall not affect the remaining provisions
hereof which shall remain in full force and effect. The Company shall determine “Cause” in its sole discretion,
which shall include, but not be limited to, your failure to execute the Restrictive Covenant Agreement or your failure to comply
with the Company’s policies and the Restrictive Covenant Agreement. Each party shall bear the costs of any legal fees and
other fees and expenses which may be incurred in respect of enforcing its respective rights under this letter. The respective
rights and obligations of the parties hereunder shall survive any termination of your employment with the Company to the extent
necessary to the intended preservation of such rights and obligations. This letter contains the entire understanding between the
parties hereto and supersedes in all respects any prior or other agreement or understanding between the Company or any affiliate
of the Company and you with respect to the subject matter hereof.

 

This
letter is intended to comply with the requirements of Section 409A of the Internal Revenue Code of 1986, as amended (“Section
409A”), and the parties hereby agree to amend this letter as and when necessary or desirable to conform to or otherwise
properly reflect any guidance issued under Section 409A after the date hereof without violating Section 409A. In case any one
or more provisions of this letter fails to comply with the provisions of Section 409A, the remaining provisions of this letter
shall remain in effect, and this letter shall be administered and applied as if the non-complying provisions were not part of
this letter. The parties in that event shall endeavor to agree upon a reasonable substitute for the non-complying provisions,
to the extent that a substituted provision would not cause this letter to fail to comply with Section 409A, and, upon so agreeing,
shall incorporate such substituted provisions into this letter. In no event whatsoever shall the Company be liable for any additional
tax, interest or penalty that may be imposed on you by Section 409A or damages for failing to comply with Section 409A. A termination
of your employment hereunder shall not be deemed to have occurred for purposes of any provision of this letter providing for the
payment of any amount or benefit constituting “deferred compensation” under Section 409A upon or following a termination
of employment unless such termination is also a “separation from service” within the meaning of Section 409A and,
for purposes of any such provision of this letter, references to a “termination,” “termination of employment”
or like terms shall mean “separation from service.” In the event that any payment or benefit made hereunder or under
any compensation plan, program or arrangement of the Company would constitute payments or benefits pursuant to a non-qualified
deferred compensation plan within the meaning of Section 409A and, at the time of your “separation from service” you
are a “specified employee” within the meaning of Section 409A, then any such payments or benefits shall be delayed
until the six-month anniversary of the date of your “separation from service”. Each payment made under this letter
shall be designated as a “separate payment” within the meaning of Section 409A. All reimbursements and in-kind benefits
provided under this letter shall be made or provided in accordance with the requirements of Section 409A to the extent that such
reimbursements or in-kind benefits are subject to Section 409A. All reimbursements for expenses paid pursuant hereto that constitute
taxable income to you shall in no event be paid later than the end of the calendar year next following the calendar year in which
you incur such expense or pay such related tax. Unless otherwise permitted by Section 409A, the right to reimbursement or in-kind
benefits under this letter shall not be subject to liquidation or exchange for another benefit and the amount of expenses eligible
for reimbursement, or in-kind benefits, provided during any taxable year shall not affect the expenses eligible for reimbursement,
or in-kind benefits to be provided, respectively, in any other taxable year.

 

[remainder
of page intentionally left blank; signature page follows]

 

    	 	4	 

    	 

    

 

Please
indicate your acceptance of the terms and conditions of this letter by signing in the space indicated below and returning one
copy of this letter to me.

 

We
look forward to working with you.

 

	 	Sincerely,
	 	 	      
	 	By:	/s/ Vuong Trieu
	 	Name: 	Vuong
    Trieu
	 	Title:	Chairman

 

	Accepted and Agreed:	 
	 	 	 
	By:	/s/ Erik
    Emerson	 
	Name: 	Erik
    Emerson	 

 

    	 	5	 

    	 

    

 

SCHEDULE
A

 

RESTRICTIVE
COVENANT AGREEMENT

 

    	 	6	 

    	 

    

 

CONFIDENTIALITY,
RESTRICTIVE COVENANT

AND
INTELLECTUAL PROPERTY AGREEMENT

 

As
a condition of my employment and/or continued employment with Marina Biotech, Inc., its subsidiaries, affiliates, successors or
assigns (collectively, the “Company”), and in consideration of my employment with the Company and my receipt
of the compensation now and hereafter paid to me by the Company, I, Erik Emerson, agree to the following (the “Agreement”):

 

1.
Confidential Information. I agree that I have had, or will have, access to the Company’s Confidential Information,
as defined herein, that such Confidential Information is valuable to the Company, and that the unauthorized release of that information
would cause serious damage to the Company. I therefore agree to hold in strictest confidence, and not to use, except for the benefit
of the Company, or to disclose to any person, firm or corporation without written authorization of the Company, any Confidential
Information of the Company. I understand that “Confidential Information” means any of the Company’s proprietary
information, technical data, trade secrets or know-how, including but not limited to, sketches and drawings, research, product
plans, products, services, customer lists and customers, markets, software, developments, inventions, processes, formulas, technology,
engineering, marketing, finances, business plans, or other business information disclosed to me by the Company either directly
or indirectly in writing, orally or by drawings or observation, including any confidential information relating to the business
and assets that were acquired by the Company from Symplmed Pharmaceuticals LLC pursuant to that certain Asset Purchase Agreement
between the Company and Symplmed Pharmaceuticals LLC dated on or about the date of this Agreement. In the event that I am required
by law to disclose any Confidential Information, I will give the Company prompt advance written notice thereof and will assist
the Company in obtaining an order to protect the Confidential Information from public disclosure.

 

2.
Inventions

 

(a)
Inventions Retained and Licensed. I have attached hereto, as Exhibit A, a list describing all inventions, designs,
original works of authorship, developments, improvements, and trade secrets which were made by me prior to my employment with
the Company (collectively referred to as “Prior Inventions”), which belong to me, which relate to the Company’s
business, products or product development, and which are not assigned to the Company hereunder. If there are no such Prior Inventions
indicated on Exhibit A, I represent that there are no such Prior Inventions. If in the course of providing services to
the Company, I incorporate into a Company product, process or design a Prior Invention owned by me or in which I have an interest,
the Company is hereby granted and shall have a nonexclusive, royalty-free, irrevocable, perpetual, worldwide license to make,
have made, modify, use and sell such Prior Invention as part of or in connection with such product, process or design.

 

    	 	 	 

    	 

    

 

(b)
Assignment of Inventions. I acknowledge that during my employment with the Company and/or during such time as I am
providing services to the Company as a consultant, contractor, or in any capacity (both my employment and/or my provision of services
are referred to collectively herein as “employment” or being “employed”), I may be expected to undertake
creative work, either alone or jointly with others, which may lead to inventions, original works of authorship, developments,
concepts, improvements, trade secrets or other intellectual property rights, whether or not patentable or registrable under copyright
or similar laws (“Inventions”). I hereby agree that all Inventions created while employed by the Company (whether
or not on the Company’s premises or using the Company’s equipment and materials or during regular business hours),
and in connection with my employment by the Company, shall be a work-for-hire and shall be the sole and exclusive property of
the Company, and I hereby assign to the Company all of my right, title and interest in and to any and all such Inventions. In
addition, any Inventions created after the termination of my employment with the Company which are based upon or derived from
Confidential Information shall be the sole and exclusive property of the Company, and I hereby assign to the Company all of my
right, title and interest in and to any and all such Inventions.

 

(c)
Patent and Copyright Registrations. I agree to assist the Company, or its designee, in every way, to secure the Company’s
rights in the Inventions and any copyrights, patents, mask work rights or other intellectual property rights relating thereto
in any and all countries, including the disclosure to the Company of all pertinent information and data with respect thereto,
the execution of all applications, specifications, oaths, assignments and all other instruments which the Company shall deem necessary
in order to apply for and obtain such rights and in order to assign and convey to the Company, its successors, assigns and nominees
the sole and exclusive rights, title and interest in and to such Inventions, and any copyrights, patents, mask work rights or
other intellectual property rights relating thereto. I further agree that my obligation to execute or cause to be executed any
such instrument or papers shall continue after the termination of this Agreement.

 

(d)
Application. I agree that the provisions of this Section 2 shall apply with respect to any and all Inventions, whether
created during my employment with the Company or any predecessor entity, or during any pre-organization period that directly apply
to the Company’s business as of the date of creation. I acknowledge that the Company and its future investors shall rely
on this representation.

 

3.
Returning Company Documents. I agree that, at the time I cease performing services for the Company, I will immediately
deliver to the Company (and will not keep in my possession, recreate or deliver to anyone else) any and all software, devices,
records, data, notes, reports, proposals, lists, correspondence, specifications, drawings, blueprints, sketches, materials, equipment,
other documents or property, including all Confidential Information, or reproductions of any aforementioned items developed by
me in connection with my employment with the Company or otherwise belonging to the Company, its successors or assigns.

 

    	 	2	 

    	 

    

 

4.
Non-Solicitation/Non-Service 

 

(a)
Non-Solicit. To the extent permitted by law, I agree that while I am employed by the Company and for a period of twelve
(12) months immediately following the termination of my employment from the Company for any reason, I shall not either directly
or indirectly:

 

(i)
hire, solicit, induce, recruit or encourage any of the Company’s employees or independent contractors to leave their employment
or end their relationship with the Company, or take away such employees or independent contractors, or attempt to solicit, induce,
recruit, encourage or take away employees and independent contractors of the Company, either for myself or for any other person
or entity; or

 

(ii)
solicit, induce, or attempt to solicit or induce any customer, vendor or client of the Company to terminate his, her or its relationship
with the Company or to encourage said customer, vendor or client to use my services or those provided by an entity with which
I am employed or affiliated to the detriment of the Company.

 

(b)
Non-Service. To the extent permitted by law, I agree that while I am employed by the Company and for a period of twelve
(12) months immediately following the termination of my employment from the Company for any reason, I shall not, directly or indirectly,
on my own behalf or on behalf of any person, firm, company or entity (whether as principal, agent, independent contractor, partner
or otherwise or by any other means) own, manage, operate, control, participate in, perform services for (whether as an employee,
consultant or otherwise), invest in, own an interest in, or otherwise establish or carry on any business or division or line of
any business in the United States which engages in a business substantially similar to or competitive with the business of the
Company at such time.

 

(c)
Reasonableness/Judicial Reformation. I agree that the restrictive covenants in this section are reasonable under the
circumstances, and I further agree that if, in the opinion of any court of competent jurisdiction, such restraint is not reasonable
in any respect, such court shall have the right, power and authority to excise or modify such provision or provisions of these
covenants as to the court shall appear not reasonable and to enforce the remainder of the covenants as so amended.

 

5.
Non-Disparagement. I agree that I will not, directly or indirectly, individually or in concert with others, engage
in any conduct or make any statement that is likely to have the effect of undermining or disparaging the reputation of the Company,
or its good will, products, or business opportunities, or that is likely to have the effect of undermining or disparaging the
reputation of any officer, director, agent, representative, shareholder or employee, past or present, of the Company.

 

6.
Equitable Relief & Remedies. I agree that it would be impossible or inadequate to measure and calculate the Company’s
damages from any breach of the covenants set forth herein. Accordingly, I agree that if I breach any of the covenants contained
herein, the Company will have available, in addition to any other right or remedy available, the right to cease making any payments
otherwise due to me (to the extent permitted by law) and the right to obtain an injunction from a court of competent jurisdiction
restraining such breach or threatened breach and to specific performance of any such provision of this Agreement. I agree that
the time periods of the restrictive covenants contained herein shall be extended by any and all periods during which I am in breach
of such restrictive covenants.

 

    	 	3	 

    	 

    

 

7.
General Provisions

 

(a)
Severability. I agree that if one or more of the provisions in this Agreement are deemed void by law, then the remaining
provisions will continue in full force and effect and, if legally permitted, such offending provision or provisions shall be replaced
with an enforceable provision or enforceable provisions that as nearly as possible effects the parties’ intent. Without
limiting the generality of the foregoing, the parties hereby expressly state their intent that, to the extent any provision of
this Agreement is unenforceable due to the scope (temporal, geographic or otherwise) being too broad, the court or arbitrator
properly adjudicating any dispute with respect thereto shall modify such provision to the minimum extent necessary to cause such
provision to be enforceable.

 

(b)
Successors and Assigns. This Agreement will be binding upon my heirs, executors, administrators and other legal representatives
and will be for the benefit of the Company, its successors, and its assigns. I acknowledge and agree that I cannot assign or transfer
this Agreement nor any rights hereunder without the express written consent of the Company, in its absolute discretion. The Company,
however, shall have the right to assign this Agreement and/or any of its rights or obligations set forth herein.

 

(c)
Survival. I agree that notwithstanding anything in this Agreement to the contrary, the provisions of this Agreement
shall survive any termination of my employment with the Company and/or termination of this Agreement, and shall remain in full
force and effect indefinitely.

 

(d)
Governing Law. This Agreement shall be construed, interpreted and governed in accordance with the laws of the State
of California, without reference to rules relating to conflicts of law.

 

(e)
Amendment. This Agreement may only be amended by written agreement of the parties hereto.

 

[remainder
of page intentionally left blank; signature page follows]

 

    	 	4	 

    	 

    

 

	 	Marina Biotech, Inc.
	 	 	 
	 	By:	/s/ Vuong Trieu
	 	Name: 	Vuong Trieu
	 	Title:	Chairman
	 	Date:
    	June 5, 2017 
	 	 	 
	 	By:	/s/ Erik
    Emerson
	 	Name: 	Erik
    Emerson
	 	Date:	June 5, 2017

 

    	 	5	 

    	 

    

 

EXHIBIT
A

 

LIST
OF PRIOR INVENTIONS

 

AND
ORIGINAL WORKS OF AUTHORSHIP

 

	Title	 	Date	 	Identifying Number
 or Brief Description
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 

 

___
No inventions or improvements

 

___
Additional Sheets Attached

 

Signature:

 

Print
Name: Erik Emerson

 

Date:
June __, 2017

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00272-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00272-of-00352.parquet"}]]